drugset / Trial / NCT04827069
A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML)
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of Clifutinib Besylate in Relapsed/refractory AML patients with FLT3-ITD mutation.
Timeline
- Start
- 2018-05-18
- Primary completion
- 2023-08-21
- Completion
- 2023-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clifutinib | Unknown | 10 mg | Oral |
| Subject | Clifutinib | Unknown | 20 mg | Oral |
| Subject | Clifutinib | Unknown | 40 mg | Oral |
| Subject | Clifutinib | Unknown | 55 mg | Oral |
| Subject | Clifutinib | Unknown | 70 mg | Oral |
| Subject | Clifutinib | Unknown | 100 mg | Oral |